Blood cancers

PBS offers flexibility on multiple myeloma drug listing restrictions

PBS gatekeepers have signalled a willingness to be flexible on restrictions that currently prevent clinicians from prescribing the best treatments for multiple myeloma such as protease inhibitor (PI) and immunomodulatory drug (IMiD) dual therapy. In a meeting with stakeholders in May, the Pharmaceutical Benefits Advisory Committee (PBAC) said it understood the frustrations created by PBS ...

Already a member?

Login to keep reading.

© 2021 the limbic